Lin28-mediated control of let-7 biogenesis
AssigneesDana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
InventorsRichard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
Life of this patent
Estimating the term…
Abstract
The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3′ terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
Claims13
A method of inhibiting Lin28A-mediated let-7 repression in a cell comprising contacting said cell with an inhibitor of TUTaseU, wherein the cell expresses Lin28A and is in a tissue in a subject, and wherein the amount of let-7 in the tissue is increased in the presence of the inhibitor relative to in the absence of the inhibitor.
A method of inhibiting tumor growth or preventing tumor or cancer metastasis in a subject in need thereof comprising administering a therapeutically effective amount of an inhibitor of a TUTase and a pharmaceutically acceptable carrier, whereby tumor growth is inhibited in the presence of the inhibitor, wherein the tumor or cancer in the subject expresses Lin28A.
Dependencies are inferred from the claim text.